世界の骨髄異形成症候群（MDS）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3993
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、99ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、骨髄異形成症候群（MDS）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他）、用途別市場規模（入院患者、外来患者）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・骨髄異形成症候群（MDS）治療薬の市場動向
・企業の競争状況、市場シェア
・骨髄異形成症候群（MDS）治療薬の種類別市場規模（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他）
・骨髄異形成症候群（MDS）治療薬の用途別市場規模（入院患者、外来患者）
・骨髄異形成症候群（MDS）治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・骨髄異形成症候群（MDS）治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・骨髄異形成症候群（MDS）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・骨髄異形成症候群（MDS）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・骨髄異形成症候群（MDS）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd.、Sandoz Inc.、Dr Reddys Laboratories Limited、Pharmascience Inc.、Accord Healthcare Ltd、Mylan N.V.）
・結論

Market Analysis and Insights: Global Myelodysplastic Syndrome (MDS) Therapeutics Market
The global Myelodysplastic Syndrome (MDS) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myelodysplastic Syndrome (MDS) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myelodysplastic Syndrome (MDS) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myelodysplastic Syndrome (MDS) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myelodysplastic Syndrome (MDS) Therapeutics market.

Global Myelodysplastic Syndrome (MDS) Therapeutics Scope and Market Size
Myelodysplastic Syndrome (MDS) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myelodysplastic Syndrome (MDS) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Others

Segment by Application
In-Patient
Out-Patient

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd.
Sandoz Inc.
Dr Reddys Laboratories Limited
Pharmascience Inc.
Accord Healthcare Ltd
Mylan N.V.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Azacitidine
1.2.3 Lenalidomide
1.2.4 Decitabine
1.2.5 Deferasirox
1.2.6 Others
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 In-Patient
1.3.3 Out-Patient
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Perspective (2016-2027)
2.2 Myelodysplastic Syndrome (MDS) Therapeutics Growth Trends by Regions
2.2.1 Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Myelodysplastic Syndrome (MDS) Therapeutics Industry Dynamic
2.3.1 Myelodysplastic Syndrome (MDS) Therapeutics Market Trends
2.3.2 Myelodysplastic Syndrome (MDS) Therapeutics Market Drivers
2.3.3 Myelodysplastic Syndrome (MDS) Therapeutics Market Challenges
2.3.4 Myelodysplastic Syndrome (MDS) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome (MDS) Therapeutics Revenue
3.4 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome (MDS) Therapeutics Revenue in 2020
3.5 Myelodysplastic Syndrome (MDS) Therapeutics Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome (MDS) Therapeutics Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome (MDS) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myelodysplastic Syndrome (MDS) Therapeutics Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Myelodysplastic Syndrome (MDS) Therapeutics Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2016-2027)
6.2 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type
6.2.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2027)
6.3 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application
6.3.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2027)
6.4 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country
6.4.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2016-2027)
7.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type
7.2.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application
7.3.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country
7.4.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2016-2027)
9.2 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type
9.2.1 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application
9.3.1 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country
9.4.1 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Details
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.1.4 Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.1.5 Novartis AG Recent Development
11.2 Celgene Corporation
11.2.1 Celgene Corporation Company Details
11.2.2 Celgene Corporation Business Overview
11.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.2.4 Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.2.5 Celgene Corporation Recent Development
11.3 Otsuka Pharmaceutical Co., Ltd.
11.3.1 Otsuka Pharmaceutical Co., Ltd. Company Details
11.3.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
11.3.3 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.3.4 Otsuka Pharmaceutical Co., Ltd. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.3.5 Otsuka Pharmaceutical Co., Ltd. Recent Development
11.4 Sandoz Inc.
11.4.1 Sandoz Inc. Company Details
11.4.2 Sandoz Inc. Business Overview
11.4.3 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.4.4 Sandoz Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.4.5 Sandoz Inc. Recent Development
11.5 Dr Reddys Laboratories Limited
11.5.1 Dr Reddys Laboratories Limited Company Details
11.5.2 Dr Reddys Laboratories Limited Business Overview
11.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.5.4 Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.5.5 Dr Reddys Laboratories Limited Recent Development
11.6 Pharmascience Inc.
11.6.1 Pharmascience Inc. Company Details
11.6.2 Pharmascience Inc. Business Overview
11.6.3 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.6.4 Pharmascience Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.6.5 Pharmascience Inc. Recent Development
11.7 Accord Healthcare Ltd
11.7.1 Accord Healthcare Ltd Company Details
11.7.2 Accord Healthcare Ltd Business Overview
11.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.7.4 Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.7.5 Accord Healthcare Ltd Recent Development
11.8 Mylan N.V.
11.8.1 Mylan N.V. Company Details
11.8.2 Mylan N.V. Business Overview
11.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.8.4 Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
11.8.5 Mylan N.V. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Azacitidine
Table 3. Key Players of Lenalidomide
Table 4. Key Players of Decitabine
Table 5. Key Players of Deferasirox
Table 6. Key Players of Others
Table 7. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions (2022-2027)
Table 13. Myelodysplastic Syndrome (MDS) Therapeutics Market Trends
Table 14. Myelodysplastic Syndrome (MDS) Therapeutics Market Drivers
Table 15. Myelodysplastic Syndrome (MDS) Therapeutics Market Challenges
Table 16. Myelodysplastic Syndrome (MDS) Therapeutics Market Restraints
Table 17. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome (MDS) Therapeutics as of 2020)
Table 20. Ranking of Global Top Myelodysplastic Syndrome (MDS) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Myelodysplastic Syndrome (MDS) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Myelodysplastic Syndrome (MDS) Therapeutics Product Solution and Service
Table 24. Date of Enter into Myelodysplastic Syndrome (MDS) Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. Novartis AG Company Details
Table 65. Novartis AG Business Overview
Table 66. Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Product
Table 67. Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 68. Novartis AG Recent Development
Table 69. Celgene Corporation Company Details
Table 70. Celgene Corporation Business Overview
Table 71. Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Product
Table 72. Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Celgene Corporation Recent Development
Table 74. Otsuka Pharmaceutical Co., Ltd. Company Details
Table 75. Otsuka Pharmaceutical Co., Ltd. Business Overview
Table 76. Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Product
Table 77. Otsuka Pharmaceutical Co., Ltd. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Otsuka Pharmaceutical Co., Ltd. Recent Development
Table 79. Sandoz Inc. Company Details
Table 80. Sandoz Inc. Business Overview
Table 81. Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product
Table 82. Sandoz Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Sandoz Inc. Recent Development
Table 84. Dr Reddys Laboratories Limited Company Details
Table 85. Dr Reddys Laboratories Limited Business Overview
Table 86. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Product
Table 87. Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 88. Dr Reddys Laboratories Limited Recent Development
Table 89. Pharmascience Inc. Company Details
Table 90. Pharmascience Inc. Business Overview
Table 91. Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product
Table 92. Pharmascience Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 93. Pharmascience Inc. Recent Development
Table 94. Accord Healthcare Ltd Company Details
Table 95. Accord Healthcare Ltd Business Overview
Table 96. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Product
Table 97. Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 98. Accord Healthcare Ltd Recent Development
Table 99. Mylan N.V. Company Details
Table 100. Mylan N.V. Business Overview
Table 101. Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021) & (US$ Million)
Table 102. Mylan N.V. Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Azacitidine Features
Figure 3. Lenalidomide Features
Figure 4. Decitabine Features
Figure 5. Deferasirox Features
Figure 6. Others Features
Figure 7. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. In-Patient Case Studies
Figure 9. Out-Patient Case Studies
Figure 10. Myelodysplastic Syndrome (MDS) Therapeutics Report Years Considered
Figure 11. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Players in 2020
Figure 16. Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myelodysplastic Syndrome (MDS) Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome (MDS) Therapeutics Revenue in 2020
Figure 18. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Region (2016-2027)
Figure 40. China Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Novartis AG Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 60. Celgene Corporation Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 61. Otsuka Pharmaceutical Co., Ltd. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 62. Sandoz Inc. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 63. Dr Reddys Laboratories Limited Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 64. Pharmascience Inc. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 65. Accord Healthcare Ltd Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 66. Mylan N.V. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Global Myelodysplastic Syndrome (MDS) Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z09720 2021年4月 105Pages
当調査資料では、骨髄異形成症候群（MDS）治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。骨髄異形成症候群（MDS）治療薬の種類別市場規模（低メチル化剤、免疫調節薬、抗貧血）、用途別市場規模（一般、ジェネリック）、地域別市場規模（北米、アメリカ、...

世界の骨髄異形成症候群（MDS）治療市場 2021：企業別、地域別、種類・用途別

Global Myelodysplastic Syndrome (MDS) Treatment Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
GIR-2104Z09721 2021年4月 104Pages
当調査資料では、骨髄異形成症候群（MDS）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。骨髄異形成症候群（MDS）治療の種類別市場規模（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス）、用途別市場規模（単系統異形成を伴う難治性血球減少...

世界の骨髄異形成症候群市場規模・現状・予測（2021年-2027年）

Global Myelodysplastic Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z3994 2021年4月 129Pages
QYResearch社発行の本調査資料では、骨髄異形成症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アルキル化剤、細胞毒性抗生物質、トポイソメラーゼ阻害剤、その他）、用途別市場規模（病院、診療所）、主要地域別市場規模（北米、アメリカ、ヨ...

世界の重症急性呼吸器症候群（SARS）治療薬市場規模・現状・予測（2021年-2027年）

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z5204 2021年4月 93Pages
QYResearch社発行の本調査資料では、重症急性呼吸器症候群（SARS）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（CEL-1000、D-3252、FDX-000、INO-4500、LCA-60、その他）、用途別市場規模（病院、診...

世界の心的外傷後ストレス障害（PTSD）治療薬市場規模・現状・予測（2021年-2027年）

Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z4715 2021年4月 99Pages
QYResearch社発行の本調査資料では、心的外傷後ストレス障害（PTSD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗うつ薬、抗不安薬）、用途別市場規模（病院、薬局、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジ...

世界の閉経後膣萎縮（PVA）治療薬市場規模・現状・予測（2021年-2027年）

Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z4709 2021年4月 93Pages
QYResearch社発行の本調査資料では、閉経後膣萎縮（PVA）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中...

世界のフォンウィルブランド病（VWD）治療薬市場規模・現状・予測（2021年-2027年）

Global Von Willebrand Disease (VWD) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z5967 2021年4月 96Pages
QYResearch社発行の本調査資料では、フォンウィルブランド病（VWD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他）、用途別市場規模（病院薬局、小売薬局、オンライン...

世界のmRNAがんワクチン・治療薬市場規模・現状・予測（2021年-2027年）

Global mRNA Cancer Vaccines and Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z3935 2021年4月 92Pages
QYResearch社発行の本調査資料では、mRNAがんワクチン・治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（がん治療用標準化MRNAワクチン、個別がん治療MRNAワクチン、感染症治療MRNAワクチン、感染予防MRNAワクチン）、用途...

世界の静脈血栓塞栓症（VTE）治療薬市場規模・現状・予測（2021年-2027年）

Global Venous thromboembolism(VTE)Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z5897 2021年4月 98Pages
QYResearch社発行の本調査資料では、静脈血栓塞栓症（VTE）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（深部静脈血栓症（DVT）、肺塞栓症（PE）、その他）、用途別市場規模（病院、外来手術センター、研究所、その他）、主要地域別...

世界の水胞性口内炎（VS）治療薬市場規模・現状・予測（2021年-2027年）

Global Vesicular Stomatitis (VS) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z5910 2021年4月 90Pages
QYResearch社発行の本調査資料では、水胞性口内炎（VS）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（症候性薬、予防接種）、用途別市場規模（獣医病院、獣医クリニック、小売薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、ア...

世界の骨髄異形成症候群（MDS）治療市場 2021：企業別、地域別、種類・用途別 The Myelodysplastic Syndrome (MDS) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizati…
世界の骨髄異形成症候群市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Myelodysplastic Syndrome Market The global Myelodysplastic Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the …
世界の骨髄異形成症候群（MDS）治療薬市場 2021：企業別、地域別、種類・用途別 The Myelodysplastic Syndrome (MDS) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
世界の重症急性呼吸器症候群（SARS）治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-s…
世界のシェーグレン症候群治療薬市場規模・現状・予測（2021年-2027年） Sjogren’s syndrome is an inflammatory disorder characterized by lymphocytic infiltrates in exocrine organs, primarily in lacrimal and salivary glands, resulting in classic sicca symptoms of dry mouth (xerostomia) and dry eyes (xerophthalmia). The disorder segmented into primary and secondary. The di…